This is a preprint.

It has not yet been peer reviewed by a journal.

The National Library of Medicine is running a pilot to include preprints that result from research funded by NIH in PMC and PubMed.

[Preprint]. 2020 May 23:2020.05.21.20109074.

doi: 10.1101/2020.05.21.20109074.

Repurposing Existing Medications for Coronavirus Disease 2019: Protocol for a Rapid and Living Systematic Review

Benjamin P Geisler^{1

2}, Lara Zahabi³, Adam E Lang⁴, Naomi Eastwood⁵, Elaine Tennant^{6

7}, Ljiljana Lukic⁸, Elad Sharon⁹, Hai-Hua Chuang^{10

11

12}, Chang-Berm Kang¹³, Knakita Clayton-Johnson¹⁴, Ahmed Aljaberi¹⁵, Haining Yu¹⁶, Chinh Bui¹⁷, Tuan Le Mau¹⁸, Wen-Cheng Li¹⁰, Debbie Teodorescu^{1

17}, Ludwig Christian Hinske², Dennis L Sun¹⁹, Farrin A Manian¹, Adam G Dunn²⁰

Affiliations

¹ Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.
² Ludwig Maximilian University, Munich, Germany.
³ McGill University, Montreal, Canada.
⁴ McDonald Army Health Center, Fort Eustis, VA, USA.
⁵ Wirral University Teaching Hospital NHS Foundation Trust, Wirral, UK.
⁶ Royal North Shore Hospital, Sydney, NSW, Australia.
⁷ University of New South Wales, Sydney, NSW, Australia.
⁸ University Hospital for Infectious Disease Zagreb "Dr. Fran Mihaljevic", Zagreb, Croatia.
⁹ National Cancer Institute, Bethesda, MD, USA.
¹⁰ Chang Gung Memorial Hospital/Chang Gung University, Taoyuan, Taiwan.
¹¹ National Taipei University of Technology, Taipei, Taiwan.
¹² Geisinger Medical Center, Danville, PA, USA.
¹³ Proof Biotechnologies, Inc., Columbia, SC, USA.
¹⁴ Portmore Hospital Complex, Portmore, Jamaica.
¹⁵ Brigham and Women's Hospital, Boston, MA, USA.
¹⁶ University of California San Francisco Medical Center, San Francisco, CA, USA.
¹⁷ Massachusetts Institute for Technology, Cambridge, MA, USA.
¹⁸ Institute of High Performance Computing, Singapore.
¹⁹ California Polytechnic State University, San Luis Obispo, CA, USA.
²⁰ University of Sydney, Sydney, NSW, Australia.

PMID: 32511471
PMCID: PMC7265692
DOI: 10.1101/2020.05.21.20109074

Repurposing Existing Medications for Coronavirus Disease 2019: Protocol for a Rapid and Living Systematic Review

Benjamin P Geisler et al. medRxiv. 2020.

[Preprint]. 2020 May 23:2020.05.21.20109074.

doi: 10.1101/2020.05.21.20109074.

Authors

Affiliations

¹ Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.
² Ludwig Maximilian University, Munich, Germany.
³ McGill University, Montreal, Canada.
⁴ McDonald Army Health Center, Fort Eustis, VA, USA.
⁵ Wirral University Teaching Hospital NHS Foundation Trust, Wirral, UK.
⁶ Royal North Shore Hospital, Sydney, NSW, Australia.
⁷ University of New South Wales, Sydney, NSW, Australia.
⁸ University Hospital for Infectious Disease Zagreb "Dr. Fran Mihaljevic", Zagreb, Croatia.
⁹ National Cancer Institute, Bethesda, MD, USA.
¹⁰ Chang Gung Memorial Hospital/Chang Gung University, Taoyuan, Taiwan.
¹¹ National Taipei University of Technology, Taipei, Taiwan.
¹² Geisinger Medical Center, Danville, PA, USA.
¹³ Proof Biotechnologies, Inc., Columbia, SC, USA.
¹⁴ Portmore Hospital Complex, Portmore, Jamaica.
¹⁵ Brigham and Women's Hospital, Boston, MA, USA.
¹⁶ University of California San Francisco Medical Center, San Francisco, CA, USA.
¹⁷ Massachusetts Institute for Technology, Cambridge, MA, USA.
¹⁸ Institute of High Performance Computing, Singapore.
¹⁹ California Polytechnic State University, San Luis Obispo, CA, USA.
²⁰ University of Sydney, Sydney, NSW, Australia.

PMID: 32511471
PMCID: PMC7265692
DOI: 10.1101/2020.05.21.20109074

Update in

Repurposing existing medications for coronavirus disease 2019: protocol for a rapid and living systematic review.
Geisler BP, Zahabi L, Lang AE, Eastwood N, Tennant E, Lukic L, Sharon E, Chuang HH, Kang CB, Clayton-Johnson K, Aljaberi A, Yu H, Bui C, Le Mau T, Li WC, Teodorescu D, Hinske LC, Sun DL, Manian FA, Dunn AG. Geisler BP, et al. Syst Rev. 2021 May 7;10(1):143. doi: 10.1186/s13643-021-01693-7. Syst Rev. 2021. PMID: 33962652 Free PMC article.

Abstract

Background: Coronavirus Disease 2019 (COVID-19) has no known specific treatments. However, there might be in vitro and early clinical data as well as evidence from Severe Acute Respiratory Syndrome and Middle Eastern Respiratory Syndrome that could inform clinicians and researchers. This systematic review aims to create priorities for future research of drugs repurposed for COVID-19.

Methods: This systematic review will include in vitro, animal, and clinical studies evaluating the efficacy of a list of 34 specific compounds and four groups of drugs identified in a previous scoping review. Studies will be identified both from traditional literature databases and pre-print servers. Outcomes assessed will include time to clinical improvement, time to viral clearance, mortality, length of hospital stay, and proportions transferred to the intensive care unit and intubated, respectively. We will use the GRADE methodology to assess the quality of the evidence.

Discussion: The challenge posed by COVID-19 requires not just a rapid review of drugs that can be repurposed but also a sustained effort to integrate new evidence into a living systematic review.

Systematic review registration: PROSPERO 2020 CRD42020175648.

Keywords: COVID-19; MERS-CoV; Middle East Respiratory Syndrome Coronavirus; SARS; SARS-CoV2; Severe Acute Respiratory Syndrome; repurposed; repurposing.

PubMed Disclaimer

Conflict of interest statement

Competing interests The authors declare that they have no competing interests.

References

1. Barro RJ, Ursúa JF, Weng J: The Coronavirus and the Great Influenza Pandemic: Lessons from the “Spanish Flu” for the Coronavirus’s Potential Effects on Mortality and Economic Activity. In. Cambridge, Mass., USA: National Bureau of Economic Research; 2020.
1. He D, Zhao S, Li Y, Zhuang Z, Cao P, Gao D, Lou Y, Yang L: History is the best model-a comparison of the COVID-19 with the 1918–19 pandemic influenza in United Kingdom. Available at SSRN 3582393 2020.
1. Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, Fu S, Gao L, Cheng Z, Lu Q et al.: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. The Lancet 2020, 395(10236):1569–1578. - PMC - PubMed
1. National Institute of Allergy and Infectious Diseases (NIAID): NIH Clinical Trial Shows Remdesivir Accelerates Recovery from Advanced COVID-19 [https://www.niaid.nih.gov/news-events/nih-clinical-trial-shows-remdesivi...] (2020). Accessed 05/19/2020.
1. Mohs RC, Greig NH: Drug discovery and development: Role of basic biological research. Alzheimers Dement (N Y) 2017, 3(4):651–657. - PMC - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

This is a preprint.

Repurposing Existing Medications for Coronavirus Disease 2019: Protocol for a Rapid and Living Systematic Review

Affiliations

Repurposing Existing Medications for Coronavirus Disease 2019: Protocol for a Rapid and Living Systematic Review

Authors

Affiliations

Update in

Abstract

Conflict of interest statement

References

Publication types

LinkOut - more resources

Full Text Sources

Miscellaneous